Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma
NCT00626444Phase 2
Key facts
- Status
- Terminated
- Start
- Feb 2008
- Primary completion
- Dec 2011
- Countries
- 1
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Modality
- Small Molecules
- Drugs
- ascorbic acid
- Conditions
- non-Hodgkin lymphoma (NHL)
01
Overview
Phase 2, open-label, single-arm trial of ascorbic acid in non-Hodgkin lymphoma (NHL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Progression-Free Survival at 10 weeks. Started Feb 2008; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Intravenous vitamin C
High dose IV ascorbic acid monotherapy
03
Who it enrols
Adults with refractory aggressive or very aggressive NHL who failed 1+ therapies and have normal G6PD status.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Duration of Response
Beyond the preview
Go deeper on NCT00626444.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00626444.